Ongoing studies of novel RAF inhibitors are of great importance in neuroncology, due to the fact that not class I MAPK/ERK pathway mutations are relatively common in brain tumors such as low-grade gliomas and pylocitic astrocytoma. Here, RAF1 is linked to glioma.